CLChristian LeGuern

Christian LeGuern

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christian LeGuern has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Kai-Christian Sonntag

    Program for Neuropsychiatric Research, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA

    2 shared publications
  • Akihiko Yasumoto

    Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA2Division of Medical Genetics, University of Washington, Seattle, Washington, USA3Department of Surgery (II), Chiba University School of Medicine, Chiba, Japan4Klinikum Mannheim GmbH, Chirurgische Klinik, Mannheim, Germany5Novartis Pharmaceuticals, Clinical Research and Development, East Hanover, New Jersey, USA6Department of Pathology, Nippon Medical School, Tokyo, Japan

    1 shared publication
  • Akira Shimizu

    Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA2Division of Medical Genetics, University of Washington, Seattle, Washington, USA3Department of Surgery (II), Chiba University School of Medicine, Chiba, Japan4Klinikum Mannheim GmbH, Chirurgische Klinik, Mannheim, Germany5Novartis Pharmaceuticals, Clinical Research and Development, East Hanover, New Jersey, USA6Department of Pathology, Nippon Medical School, Tokyo, Japan

    1 shared publication
  • David H. Sachs

    Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA2Division of Medical Genetics, University of Washington, Seattle, Washington, USA3Department of Surgery (II), Chiba University School of Medicine, Chiba, Japan4Klinikum Mannheim GmbH, Chirurgische Klinik, Mannheim, Germany5Novartis Pharmaceuticals, Clinical Research and Development, East Hanover, New Jersey, USA6Department of Pathology, Nippon Medical School, Tokyo, Japan

    1 shared publication
  • David W. Emery

    Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA2Division of Medical Genetics, University of Washington, Seattle, Washington, USA3Department of Surgery (II), Chiba University School of Medicine, Chiba, Japan4Klinikum Mannheim GmbH, Chirurgische Klinik, Mannheim, Germany5Novartis Pharmaceuticals, Clinical Research and Development, East Hanover, New Jersey, USA6Department of Pathology, Nippon Medical School, Tokyo, Japan

    1 shared publication
  • Gary Haller

    Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA2Division of Medical Genetics, University of Washington, Seattle, Washington, USA3Department of Surgery (II), Chiba University School of Medicine, Chiba, Japan4Klinikum Mannheim GmbH, Chirurgische Klinik, Mannheim, Germany5Novartis Pharmaceuticals, Clinical Research and Development, East Hanover, New Jersey, USA6Department of Pathology, Nippon Medical School, Tokyo, Japan

    1 shared publication

Latest Publications

  • Tolerogenic property of MHC class I and class II molecules: lessons from a gene therapy approach

    by Christian LeGuern

    Conditions allowing the development of a stable state of hematopoietic chimerism, i.e., the coexistence of foreign and recipient hematopoietic cells in the same individual, remain the most effective means to produce immune tolerance to antigens expressed by foreign cells/grafts. However, heavy immunosuppression is required to achieve chimerism and as such has limited clinical application. MHC antigens being the primary targets of immune responses, we pioneered an innovative approach in which foreign MHC genes were first introduced in bone marrow cells of recipients of subsequent grafts expressing the same MHC antigens. This strategy produced MHC class I (MHC I) or class II (MHC II) molecular chimerism, did not require heavy conditioning, and enabled long-term transplant acceptance in rodents as well as large animals. However, recent developments have indicated, that although the outcomes of gene transfer were similar, the mechanism of tolerance induction by MHC I and MHC II gene transfer were markedly different. This review examines the tolerance mechanism arising after MHC gene transfer to infer that MHC II gene therapy is clinically more relevant since the transfer of a single gene enables broad tolerance to all graft antigens via the production of MHC II peptides for selective activation of regulatory T cells (T-regs).


  • Switching on Immune Regulation to Prevent Graft Rejection

    by Christian LeGuern

    Achieving immune tolerance to allografts is an important goal of clinical transplantation. Although remarkable achievements in graft survival have been made with the use of immunosuppressive drugs, the “operational” tolerance that these molecules provide is, unfortunately, associated with a cohort of complications that develop in permanently immunosuppressed patients. More suitable approaches to pharmaceutical immunosuppression should, ideally, provide long-term, graft-specific tolerance, while preserving an intact immunity to pathogens and tumors. Alternative strategies have been devised from the study of animal models of T-cell tolerance to self-antigens. Notably, it has been shown that healthy immune systems use at least two complementary mechanisms to harness the autoreactivity of T lymphocytes: deletion of high-affinity T-cell clones and down-regulation of the less-reactive subset. The adaptation of the deletional mechanism to experimental transplantation has led to the induction of donor-specific tolerance through the creation of donor/recipient bone marrow chimera (1). In contrast, regulatory pathways have been invoked through the recruitment of specialized regulatory T-cell subsets (2). Although effective at inducing donor-specific tolerance in mice, the mixed chimerism approach remains difficult to apply to clinical settings because of complications associated with the conditioning regimen used and the development of graft-versus-host disease. Thus, the recent characterization of regulatory cell subsets, as powerful repressors of alloreactive T cells, has renewed the interest in the use of T-cell regulation as a means to harnessing graft rejection (3). The principal subpopulation of regulatory T lymphocytes (Tregs) includes CD4+CD25+ cells that have been subdivided into two functional subsets. The T-regulatory type 1 (Tr1)/T-helper (Th) 3 subset, also known as adaptive/induced Tregs, displays T-cell receptor (TCR) specificities for nominal antigens (i.e., the same TCR specificities as carried by the T cells that they suppress). It differentiates peripherally and represses effector T-cell functions by local release of inhibitory cytokines such as transforming growth factor-β and interleukin-10. Conversely, the TCR specificity of natural Tregs (the second subset) is still unknown, although they differentiate in the thymus and act in the periphery through an initial cell contact with activated effector cells. In addition to being CD4+CD25+, both the natural and adaptive Tregs shared a number of surface and intracellular markers, including cytotoxic T lymphocyte antigen (CTLA)-4 and glucocorticoid-induced tumor necrosis factor receptor (GITR), which are not specific to these regulatory subsets. The understanding of the mechanism of Treg-mediated suppression and the therapeutic manipulation of these cells to prevent rejection of allogeneic grafts requires identification of Treg-specific markers and further knowledge of their TCR specificity. Recently, two Treg-specific markers have been described: the LAG-3 surface molecule, a CD4 homolog that also binds major histocompatibility complex class II (4), and the FoxP3 nuclear protein, a transcriptional repressor of the forkhead/winged-helix family. Considerable attention has been given to FoxP3 when it was discovered that its forced expression in naïve T cells converted them into functional Tregs (5). This seminal observation also suggested that it was possible to customize T effector cells to become functional Tregs with predefined TCR specificity. Tregs, created by FoxP3 gene transfer, have been successfully used to prevent and alleviate wasting disease (6) and colitis (5), but have not been tested for their ability to repress responses to allografts. In this regard, the report of J.-G. Chai et al. in this issue of Transplantation constitutes an important step in the understanding of the mechanism of regulatory tolerance to transplants. The model uses female mice that express a transgenic TCR directed at the male H-Y antigen and are recipients of male (H-Y+) skin grafts.

  • Potential role of major histocompatibility complex class II peptides in regulatory tolerance to vascularized grafts.

    by Christian LeGuern

    The inactivation of persisting T lymphocytes reactive to self- and non-self-antigens is a major arm of operational immune tolerance in mammals. Silencing of such T cells proceeds mostly by means of suppression, a process that is mediated by regulatory T-cell subsets and especially by CD4(+)CD(25high) regulatory T cells (Treg). Although Treg activation and ensuing suppressive activity appear to be major histocompatibility complex class II dependent, the fine specificity of Treg T-cell receptors has not yet been elucidated. Recent data from the author's laboratory on a class II gene therapy induction of tolerance to allogeneic kidney grafts suggest that class II peptides are involved as generic signals for Treg activation. A brief compilation of results that would support this hypothesis is discussed in the present article.


  • Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity*

    by Ulrike B. Matter-Reissmann, Kai-Christian Sonntag, Urs O. Gilli, Christian Leguern, Marten K. J. Schneider, Jorg D. Seebach

    Several human leukocyte subsets including natural killer (NK) cells, cytotoxic T lymphocytes (CTL), and polymorphonuclear neutrophils (PMN) participate in cellular immune responses directed against vascularized pig-to-human xenografts. As these leukocytes express the death receptor Fas either constitutively (PMN) or upon activation (NK, CTL), we explored in vitro whether the transgenic expression of Fas ligand (FasL) on porcine endothelial cells (EC) is a valuable strategy to protect porcine xenografts. The porcine EC line 2A2 was stably transfected with human FasL (2A2-FasL) and interactions of 2A2-FasL with human leukocytes were analyzed using functional assays for apoptosis, cytotoxicity, chemotaxis, adhesion under shear stress, and transmigration. FasL expressed on porcine EC induced apoptosis in human NK and T cells, but did not protect porcine EC against killing mediated by human NK cells. 2A2-FasL released soluble FasL, which induced strong chemotaxis in human PMN. Adhesion under shear stress of PMN on 2A2-FasL cells was increased whereas transendothelial migration was decreased. In contrast, FasL had no effect on the adhesion of NK cells but increased their transmigration through porcine EC. Although FasL expression on porcine EC is able to induce apoptosis in human effector cells, it did not provide protection against xenogeneic cytotoxicity. The observed impact of FasL on adhesion and transendothelial migration provides evidence for novel biological functions of FasL.


  • Open Access

    Tolerance to solid organ transplants through transfer of MHC class II genes

    by Kai-C. Sonntag, David W. Emery, Akihiko Yasumoto, Gary Haller, Sharon Germana, Tomasz Sablinski, Akira Shimizu, Kazuhiko Yamada, Hideaki Shimada, Scott Arn, et al.

    Donor/recipient MHC class II matching permits survival of experimental allografts without permanent immunosuppression, but is not clinically applicable due to the extensive polymorphism of this locus. As an alternative, we have tested a gene therapy approach in a preclinical animal model to determine whether expression of allogeneic class II transgenes (Tg’s) in recipient bone marrow cells would allow survival of subsequent Tg-matched renal allografts. Somatic matching between donor kidney class II and the recipient Tg’s, in combination with a short treatment of cyclosporine A, prolonged graft survival with DR and promoted tolerance with DQ. Class II Tg expression in the lymphoid lineage and the graft itself were sequentially implicated in this tolerance induction. These results demonstrate the potential of MHC class II gene transfer to permit tolerance to solid organ allografts.